Join Paratek at the American Podiatric Medical Association (APMA) National Annual Scientific Meeting in Washington, D.C. from August 8-10. Visit us at Booth 815 in the Washington D.C. Convention Center to talk to us about the role our product plays in the treatment of ABSSSI (Acute Bacterial Skin and Skin Structure Infections). You can find us on the interactive map here: https://bit.ly/4fpFMuu We look forward to seeing you there! #APMA2024 #APMANational2024 #AMR
Paratek Pharmaceuticals
Pharmaceutical Manufacturing
Boston, MA 17,101 followers
Developing transformative solutions for patients with infectious diseases and other difficult to treat conditions
About us
Positive outcomes. Positive patient stories. These are our priorities at Paratek Pharmaceuticals. As a commercial-stage biopharmaceutical company, we develop transformative solutions for patients with infectious diseases and other difficult to treat conditions, and we believe that we have the right people, the right knowledge and the right drug to make a difference in patients’ lives. Our Mission To create positive stories for patients, physicians and caregivers based on trust and integrity. To accomplish this, our employees work hard to turn everyday decisions into everyday triumphs that advance our technology and strengthen Paratek. Our Vision To be a leading independent biopharmaceutical company providing novel life-saving products for life-threatening diseases or other public health threats.
- Website
-
http://www.paratekpharma.com
External link for Paratek Pharmaceuticals
- Industry
- Pharmaceutical Manufacturing
- Company size
- 51-200 employees
- Headquarters
- Boston, MA
- Type
- Public Company
- Founded
- 1996
Locations
-
Primary
75 Park Plaza
4th Floor
Boston, MA 02116, US
-
1000 First Avenue
Suite 200
King of Prussia, PA 19406, US
Employees at Paratek Pharmaceuticals
Updates
-
We’re proud to have joined the healthcare community in recognizing #WorldNTMAwarenessDay. Together, we’re raising awareness of nontuberculous mycobacterial (NTM) pulmonary disease to support patients and families impacted by NTM, and advocating for better resources and earlier detection to avoid delayed diagnoses. A big thank you to the dedicated team and the ongoing commitment to finding better treatments for patients with #NTM. Learn more about our efforts: https://bit.ly/4fr4drk #NTMCommunity
-
Sending best wishes to the Olympic Team USA 8-man rowers including Peter Chatain, son of Paratek field sales representative, Kim Chatain. They’ll be rowing in the finals this Saturday, 8/3. We’re rooting for you stateside, Peter! Tune in to watch the race live at 5:10 a.m. ET: https://bit.ly/3WxmUku #TeamUSA #Olympics #Rowing
-
Paratek Pharmaceuticals has completed a five-year microbiologic surveillance study of its antibiotic, showing no change in in vitro potency and no emergence of resistance. As part of our commitment to addressing antimicrobial resistance (AMR), we’re continuing surveillance studies. See Paratek’s press release: https://bit.ly/4fsK1FK Biomedical Advanced Research and Development Authority (BARDA) U.S. Department of Health and Human Services (HHS) #drugdevelopment #biopharma #AMR
-
ICYMI: The 2024 Vivli #AMRSurveillance Data Challenge submission deadline has been extended until August 11! Join the fight against anti-microbial resistance (AMR), a critical public health issue and contribute to life-saving research – and the chance to earn monetary awards to support your research. Learn more: https://bit.ly/3zZKdMs #sponsors #antibiotics #healthcare
📢 DEADLINE EXTENDED! Important opportunity for all those working in #AMR #surveillance to enter this exciting challenge. The 2024 #AMRSurveillance Data Challenge, funded by Global Antibiotic R&D Partnership (GARDP), Paratek Pharmaceuticals, Pfizer and Vivli is now OPEN. Head to https://lnkd.in/djaXB-PX to read about the challenge and how to enter this exciting challenge! Expressions of interest must be received by August 11, 2024. 📢 #AntimicrobialResistance #OneHealth American Society for Microbiology ESCMID - European Society of Clinical Microbiology and Infectious Diseases CARB-X
-
Diane Anastasiou MT (ASCP), Director, Microbiology, is a judge for the 2024 Vivli #AMRSurveillance Data Challenge. As proud supporters of this organization and this challenge, we understand firsthand the importance of sharing and analyzing #AMR data to advance research to develop solutions to combat this growing global health crisis. #sponsors Deadline for submissions is Sunday, July 28. Learn more and help combat anti-microbial resistance. #Antibiotics #healthcare
Meet the judges reviewing solutions from the 2024 Vivli #AMRSurveillance Data Challenge: https://lnkd.in/e-8e5ngd Submissions are due by Sunday, July 28 - find out more and get involved in combating #AntimicrobialResistance! Diane Anastasiou MT (ASCP) Patricia Bradford Ana C Gales Direk Limmathurotsakul Anand Manoharan Marc Mendelson Seamus O'Brien Katherine Perez
-
At Paratek, our people are the source and foundation of our innovation and culture. Joanne Tatem, Ph.D., Executive Director of Project Management, is one of those people. Bringing more than 25 years of industry experience with increasing leadership responsibility, Joanne has leveraged that significant expertise at Paratek leading projects and partnerships that make a significant impact for our business, customers and patients. Earlier this year, she received the 2024 Levy-Gilbert CEO Award to recognize her achievements and commitment to Paratek’s values.
-
There's still time to register for tomorrow's Global Antibiotic R&D Partnership (GARDP) webinar, "Progressing an antibacterial drug discovery project – a small medium enterprise (SME) perspective." Featuring our Head of Microbiology and Nonclinical Development, Alisa Serio, this webinar will explore key considerations and challenges faced when progressing antibacterial drug discovery projects. Register NOW: https://bit.ly/3xespMw #AMR #publichealth
-
#AANP24 Booth #1400: Find Paratek during the American Association of Nurse Practitioners National Conference in Nashville. Visit the Exhibit Hall to find our team ready to discuss our product's role in the treatment of CABP (Community-Acquired Bacterial Pneumonia) and ABSSSI (Acute Bacterial Skin and Skin Structure Infections) in hospitals, communities and public health settings. https://bit.ly/3Rp6x80 #biopharma
-
Explore the challenges and solutions of antibacterial drug discovery with Alisa Serio PhD (she/her), our Executive Director of Microbiology & Nonclinical Development, during this Global Antibiotic R&D Partnership (GARDP) webinar. Alisa will dive into the drug discovery process through approval and commercialization and strategic considerations for each phase of an antibacterial program within a Small Medium Enterprise. Bring your questions for the live Q&A! Register here: https://bit.ly/3xespMw #AMR #biopharma #publichealth